2017-03-22,ChemoCentryx Receives FDA Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
2017-03-14,ChemoCentryx Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-01,ChemoCentryx To Hold Fourth Quarter 2016 Financial Results Conference Call On Tuesday, March 14, 2017
2017-02-28,ChemoCentryx To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-14,Vifor Pharma And ChemoCentryx Announce Expansion Of Avacopan Agreement For Rare Renal Diseases
2017-01-20,ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer
2017-01-09,ChemoCentryx Provides Corporate Update Including Development Strategy For Lead Programs In Rare Renal Diseases
2017-01-04,ChemoCentryx To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Vifor Pharma And ChemoCentryx Announce Expansion Of Kidney Health Alliance To Include CCX140 To Treat Renal Diseases
2016-11-07,ChemoCentryx Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,ChemoCentryx Announces Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials ('CLEAR' And 'CLASSIC') Of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
2016-10-28,ChemoCentryx To Hold Third Quarter 2016 Financial Results Conference Call On Monday, November 7, 2016
2016-10-20,ChemoCentryx Appoints Henry A. McKinnell, Jr. To Board Of Directors
2016-10-18,ChemoCentryx's CCR2 Inhibitor CCX872 Shown To Reduce Liver Fibrosis In NASH Models
2016-10-17,ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016
2016-09-01,ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer
2016-08-25,ChemoCentryx To Present At The Baird 2016 Global Healthcare Conference
2016-08-08,ChemoCentryx Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,ChemoCentryx To Hold Second Quarter 2016 Financial Results Conference Call On Monday, August 8, 2016
2016-06-29,ChemoCentryx To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-22,First Week of CCXI February 2017 Options Trading
2016-06-16,ChemoCentryx Announces Positive Top-Line Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study And Advances Plans To Initiate Phase III Development
2016-06-01,ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis
2016-05-25,ChemoCentryx To Present At The Jefferies 2016 Healthcare Conference
2016-05-23,ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 At The 53rd ERA-EDTA Congress
2016-05-12,5 Breakout Stocks Under $10 Set to Soar
2016-05-12,ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting
2016-05-11,ChemoCentryx To Host R&D Day On May 18, 2016
2016-05-10,ChemoCentryx Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-10,Vifor Pharma Licenses Rights To Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets
2016-05-05,ChemoCentryx To Hold First Quarter 2016 Financial Results Conference Call On Tuesday, May 10, 2016
2016-04-28,ChemoCentryx Receives FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168 For Treatment Of ANCA-Associated Vasculitis
2016-04-18,ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-01,5 Stocks Poised for Big Breakouts
2016-03-14,ChemoCentryx Reports Fourth Quarter 2015 Financial Results And Provides Corporate Update
2016-02-29,ChemoCentryx To Hold Fourth Quarter 2015 Financial Results Conference Call On Monday, March 14, 2016
2016-02-25,ChemoCentryx To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-01-07,ChemoCentryx To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-06,ChemoCentryx is Now Oversold (CCXI)
2016-01-06,ChemoCentryx Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168
2015-11-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-11-09,ChemoCentryx Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,ChemoCentryx Highlights Results In Diabetic Nephropathy And Atypical Hemolytic Uremic Syndrome At The American Society Of Nephrology Annual Meeting
2015-11-04,ChemoCentryx Announces Immuno-Oncology Data Presentations At The AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Meeting
2015-10-29,ChemoCentryx To Hold Third Quarter 2015 Financial Results Conference Call On Monday, November 9, 2015
2015-09-02,ChemoCentryx To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-06,ChemoCentryx Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-06,Oversold Conditions For ChemoCentryx (CCXI)
2015-07-30,ChemoCentryx Announces Changes To Its Board Of Directors
2015-07-29,ChemoCentryx To Hold Second Quarter 2015 Financial Results Conference Call On Thursday, August 6, 2015
2015-05-29,Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At The 52nd ERA-EDTA Congress
2015-05-26,Positive Clinical Data From ChemoCentryx Phase II Trial In Diabetic Nephropathy To Be Presented At The 52nd Annual ERA-EDTA Congress
2015-05-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-05-06,ChemoCentryx Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-29,Relative Strength Alert For ChemoCentryx
2015-04-22,ChemoCentryx To Hold First Quarter 2015 Financial Results Conference Call On Wednesday, May 6, 2015
2015-04-20,ChemoCentryx Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer
2015-03-12,ChemoCentryx Reports Fourth Quarter 2014 Financial Results And Provides Corporate Update
2015-02-26,ChemoCentryx To Hold Fourth Quarter 2014 Financial Results Conference Call On Thursday, March 12, 2015
2015-02-17,ChemoCentryx To Present At The Cowen And Company 35th Annual Health Care Conference
2015-01-26,First Week Of CCXI August 21st Options Trading
2015-01-16,Commit To Buy ChemoCentryx At $5, Earn 26.9% Annualized Using Options
2015-01-06,ChemoCentryx To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-12,ChemoCentryx Announces Positive Results In Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
2014-12-11,ChemoCentryx To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase II Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor
2014-12-04,Relative Strength Alert For ChemoCentryx
2014-12-04,ChemoCentryx Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis
2014-11-20,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA
2014-11-17,ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
2014-11-06,ChemoCentryx To Present At Two Upcoming Investor Conferences
2014-11-05,ChemoCentryx Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-10-22,ChemoCentryx To Hold Third Quarter 2014 Financial Results Conference Call On Wednesday, November 5, 2014
2014-10-21,ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study
2014-10-20,ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease
2014-10-02,ChemoCentryx Becomes Oversold (CCXI)
2014-09-22,ChemoCentryx Appoints Israel F. Charo, M.D., Ph.D., Senior Vice President Of Research
2014-08-05,ChemoCentryx Announces Financial Results For The Second Quarter Ended June 30, 2014
2014-07-23,ChemoCentryx To Hold Second Quarter 2014 Financial Results Conference Call On Tuesday, August 5, 2014
2014-06-03,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
2014-06-02,ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements
2014-05-08,ChemoCentryx Announces Financial Results For The First Quarter Ended March 31, 2014
2014-05-02,3 Stocks Under $10 Moving Higher
2014-04-29,ChemoCentryx To Hold First Quarter 2014 Financial Results Conference Call On Thursday, May 8, 2014
2014-04-15,ChemoCentryx is Now Oversold (CCXI)
2014-03-27,ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. To Chief Strategic Development Role And Head Of Immuno-Oncology
2014-03-13,ChemoCentryx Announces Financial Results For The Quarter And Year Ended December 31, 2013
2014-03-03,ChemoCentryx To Hold Fourth Quarter And Year-End 2013 Financial Results Conference Call On Thursday, March 13, 2014
2014-02-27,Short Interest In ChemoCentryx Makes 16% Move
2014-02-25,ChemoCentryx To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-21,5 Stocks Poised for Breakouts
2014-01-13,ChemoCentryx Stock Sees Short Interest Move 38.4% Lower
2014-01-10,5 Under-$10 Biotech Stocks to Watch
2014-01-08,ChemoCentryx To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2014-01-02,Interesting CCXI Put And Call Options For August 16th
2013-12-03,ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data In ANCA-Associated Renal Vasculitis
2013-11-25,5 Stocks Poised for Breakouts
2013-11-15,4 Stocks Under $10 to Trade for Breakouts
2013-11-12,Oversold Conditions For ChemoCentryx (CCXI)
2013-11-07,ChemoCentryx Announces Financial Results For The Quarter Ended September 30, 2013
2013-11-07,Top Insider Trades: PBYI USAK RT CCXI
2013-11-06,ChemoCentryx To Present At The 2013 Credit Suisse Annual Health Care Conference
2013-11-04,Top Insider Trades: ACHN, CCXI, ACCL, WLT
2013-10-31,ChemoCentryx, Inc. To Hold Third Quarter 2013 Financial Results Conference Call On Thursday, November 7, 2013
2013-10-18,ChemoCentryx Becomes Oversold (CCXI)
2013-10-16,5 Stocks With Big Insider Buying
2013-10-11,Short Interest In ChemoCentryx Moves 91.5% Higher
2013-10-11,Top Insider Trades: CCXI HA USCR ACW
2013-10-09,5 Stocks Insiders Are Scooping Up
2013-10-08,Top Insider Trades: CCXI AYR FATE CFIS
2013-09-23,ChemoCentryx To Present At BioCentury's NewsMakers In The Biotech Industry Conference
2013-09-18,ChemoCentryx To Regain Global Rights For Vercirnon From GlaxoSmithKline
2013-09-18,4 Biotech Stocks Under $10 to Watch
2013-09-17,Ratings Changes Today
2013-09-16,Top Insider Trades: CCXI, GBDC, MVC, FUND
2013-09-10,ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
2013-09-10,ChemoCentryx Announces Top-Line Interim Results For CCX140, An Orally Administered CCR2 Inhibitor, In An Ongoing 52 Week Phase II Trial In Patients With Diabetic Nephropathy
2013-09-04,ChemoCentryx To Present At Two Upcoming Investor Conferences
2013-08-23,ChemoCentryx Announces GlaxoSmithKline's Release Of Top-Line Results From The SHIELD-1 Phase III Study Of Vercirnon
2013-08-12,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2013
2013-08-09,ChemoCentryx Is Now Oversold (CCXI)
2013-08-01,ChemoCentryx, Inc. To Hold Second Quarter 2013 Financial Results Conference Call On Monday, August 12, 2013
2013-07-25,ChemoCentryx Stock Sees Short Interest Make 124.7% Move
2013-06-26,Commit To Buy ChemoCentryx At $12.50, Earn 24.8% Annualized
2013-06-19,ChemoCentryx Announces Completion Of Target Enrollment Of CCX140 Phase II Clinical Trial In Diabetic Nephropathy
2013-06-07,Biotech Stock Mailbag: 2013 Clinical Trials Calendar
2013-06-05,ChemoCentryx To Present At Two Upcoming Healthcare Conferences And Ring Opening Bell At The NASDAQ Stock Market
2013-05-28,ChemoCentryx Announces Appointment Of Health Care Insurance Executive Ira Klein, MD, To Company's Board Of Directors
2013-05-21,ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
2013-05-15,ChemoCentryx To Host Analyst Day
2013-05-13,ChemoCentryx Announces Financial Results For The Quarter Ended March 31, 2013
2013-05-10,Short Interest In ChemoCentryx Plummets 66%
2013-05-02,ChemoCentryx, Inc. To Hold First Quarter 2013 Financial Results Conference Call On Monday, May 13, 2013
2013-05-02,ChemoCentryx To Present At Bank Of America Merrill Lynch Healthcare Conference
2013-04-22,ChemoCentryx Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Over-Allotment Option
2013-04-16,ChemoCentryx Announces Pricing Of Follow-On Offering
2013-04-15,ChemoCentryx Announces Proposed Public Offering Of Common Stock
2013-03-13,ChemoCentryx Announces 2012 Fourth Quarter And Year-End Financial Results
2013-02-28,ChemoCentryx, Inc. To Hold Fourth Quarter And Year-End 2012 Financial Results Conference Call On Wednesday, March 13, 2013
2013-02-20,ChemoCentryx To Present At Upcoming Investor Conferences
2013-02-06,ChemoCentryx To Present At 15th Annual BIO CEO & Investor Conference
2013-01-07,ChemoCentryx Advances A New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
2013-01-03,ChemoCentryx To Present At The 31st Annual J.P. Morgan Healthcare Conference
2012-10-24,ChemoCentryx To Report Data For CCX140, An Orally Administered CCR2 Inhibitor, At The American Society Of Nephrology's Kidney Week 2012
2012-10-02,ChemoCentryx Reports Data For CCX872, The Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, In A Preclinical Model Of Diabetic Nephropathy
2012-08-30,ChemoCentryx To Present At The BioCentury NewsMakers In The Biotech Industry Conference
2012-08-10,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2012
2012-04-12,ChemoCentryx To Present At The 19th Annual Future Leaders In The Biotech Industry Conference
,
2017-03-22,ChemoCentryx Receives FDA Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
2017-03-14,ChemoCentryx Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-10,Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
2017-03-01,ChemoCentryx To Hold Fourth Quarter 2016 Financial Results Conference Call On Tuesday, March 14, 2017
2017-02-28,ChemoCentryx To Present At The Cowen And Company 37th Annual Health Care Conference
2017-02-14,Vifor Pharma And ChemoCentryx Announce Expansion Of Avacopan Agreement For Rare Renal Diseases
2017-01-20,ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer
2017-01-09,ChemoCentryx Provides Corporate Update Including Development Strategy For Lead Programs In Rare Renal Diseases
2017-01-04,ChemoCentryx To Present At The 35th Annual J.P. Morgan Healthcare Conference
2016-12-22,Vifor Pharma And ChemoCentryx Announce Expansion Of Kidney Health Alliance To Include CCX140 To Treat Renal Diseases
2016-11-07,ChemoCentryx Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-07,ChemoCentryx Announces Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials ('CLEAR' And 'CLASSIC') Of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
2016-10-28,ChemoCentryx To Hold Third Quarter 2016 Financial Results Conference Call On Monday, November 7, 2016
2016-10-20,ChemoCentryx Appoints Henry A. McKinnell, Jr. To Board Of Directors
2016-10-18,ChemoCentryx's CCR2 Inhibitor CCX872 Shown To Reduce Liver Fibrosis In NASH Models
2016-10-17,ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016
2016-09-01,ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer
2016-08-25,ChemoCentryx To Present At The Baird 2016 Global Healthcare Conference
2016-08-08,ChemoCentryx Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,ChemoCentryx To Hold Second Quarter 2016 Financial Results Conference Call On Monday, August 8, 2016
2016-06-29,ChemoCentryx To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-22,First Week of CCXI February 2017 Options Trading
2016-06-16,ChemoCentryx Announces Positive Top-Line Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study And Advances Plans To Initiate Phase III Development
2016-06-01,ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis
2016-05-25,ChemoCentryx To Present At The Jefferies 2016 Healthcare Conference
2016-05-23,ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 At The 53rd ERA-EDTA Congress
2016-05-12,5 Breakout Stocks Under $10 Set to Soar
2016-05-12,ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting
2016-05-11,ChemoCentryx To Host R&D Day On May 18, 2016
2016-05-10,ChemoCentryx Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-10,Vifor Pharma Licenses Rights To Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets
2016-05-05,ChemoCentryx To Hold First Quarter 2016 Financial Results Conference Call On Tuesday, May 10, 2016
2016-04-28,ChemoCentryx Receives FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168 For Treatment Of ANCA-Associated Vasculitis
2016-04-18,ChemoCentryx Announces Immuno-Oncology Data Presentation At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-01,5 Stocks Poised for Big Breakouts
2016-03-14,ChemoCentryx Reports Fourth Quarter 2015 Financial Results And Provides Corporate Update
2016-02-29,ChemoCentryx To Hold Fourth Quarter 2015 Financial Results Conference Call On Monday, March 14, 2016
2016-02-25,ChemoCentryx To Present At The Cowen And Company 36th Annual Healthcare Conference
2016-01-07,ChemoCentryx To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-06,ChemoCentryx is Now Oversold (CCXI)
2016-01-06,ChemoCentryx Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168
2015-11-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-11-09,ChemoCentryx Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-05,ChemoCentryx Highlights Results In Diabetic Nephropathy And Atypical Hemolytic Uremic Syndrome At The American Society Of Nephrology Annual Meeting
2015-11-04,ChemoCentryx Announces Immuno-Oncology Data Presentations At The AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Meeting
2015-10-29,ChemoCentryx To Hold Third Quarter 2015 Financial Results Conference Call On Monday, November 9, 2015
2015-09-02,ChemoCentryx To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-06,ChemoCentryx Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-06,Oversold Conditions For ChemoCentryx (CCXI)
2015-07-30,ChemoCentryx Announces Changes To Its Board Of Directors
2015-07-29,ChemoCentryx To Hold Second Quarter 2015 Financial Results Conference Call On Thursday, August 6, 2015
2015-05-29,Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At The 52nd ERA-EDTA Congress
2015-05-26,Positive Clinical Data From ChemoCentryx Phase II Trial In Diabetic Nephropathy To Be Presented At The 52nd Annual ERA-EDTA Congress
2015-05-12,ChemoCentryx To Present At Two Upcoming Investor Conferences
2015-05-06,ChemoCentryx Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-29,Relative Strength Alert For ChemoCentryx
2015-04-22,ChemoCentryx To Hold First Quarter 2015 Financial Results Conference Call On Wednesday, May 6, 2015
2015-04-20,ChemoCentryx Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer
2015-03-12,ChemoCentryx Reports Fourth Quarter 2014 Financial Results And Provides Corporate Update
2015-02-26,ChemoCentryx To Hold Fourth Quarter 2014 Financial Results Conference Call On Thursday, March 12, 2015
2015-02-17,ChemoCentryx To Present At The Cowen And Company 35th Annual Health Care Conference
2015-01-26,First Week Of CCXI August 21st Options Trading
2015-01-16,Commit To Buy ChemoCentryx At $5, Earn 26.9% Annualized Using Options
2015-01-06,ChemoCentryx To Present At The 33rd Annual J.P. Morgan Healthcare Conference
2014-12-12,ChemoCentryx Announces Positive Results In Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
2014-12-11,ChemoCentryx To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase II Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor
2014-12-04,Relative Strength Alert For ChemoCentryx
2014-12-04,ChemoCentryx Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis
2014-11-20,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA
2014-11-17,ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
2014-11-06,ChemoCentryx To Present At Two Upcoming Investor Conferences
2014-11-05,ChemoCentryx Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-10-22,ChemoCentryx To Hold Third Quarter 2014 Financial Results Conference Call On Wednesday, November 5, 2014
2014-10-21,ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study
2014-10-20,ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease
2014-10-02,ChemoCentryx Becomes Oversold (CCXI)
2014-09-22,ChemoCentryx Appoints Israel F. Charo, M.D., Ph.D., Senior Vice President Of Research
2014-08-05,ChemoCentryx Announces Financial Results For The Second Quarter Ended June 30, 2014
2014-07-23,ChemoCentryx To Hold Second Quarter 2014 Financial Results Conference Call On Tuesday, August 5, 2014
2014-06-03,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
2014-06-02,ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements
2014-05-08,ChemoCentryx Announces Financial Results For The First Quarter Ended March 31, 2014
2014-05-02,3 Stocks Under $10 Moving Higher
2014-04-29,ChemoCentryx To Hold First Quarter 2014 Financial Results Conference Call On Thursday, May 8, 2014
2014-04-15,ChemoCentryx is Now Oversold (CCXI)
2014-03-27,ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. To Chief Strategic Development Role And Head Of Immuno-Oncology
2014-03-13,ChemoCentryx Announces Financial Results For The Quarter And Year Ended December 31, 2013
2014-03-03,ChemoCentryx To Hold Fourth Quarter And Year-End 2013 Financial Results Conference Call On Thursday, March 13, 2014
2014-02-27,Short Interest In ChemoCentryx Makes 16% Move
2014-02-25,ChemoCentryx To Present At The Cowen And Company 34th Annual Health Care Conference
2014-02-21,5 Stocks Poised for Breakouts
2014-01-13,ChemoCentryx Stock Sees Short Interest Move 38.4% Lower
2014-01-10,5 Under-$10 Biotech Stocks to Watch
2014-01-08,ChemoCentryx To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2014-01-02,Interesting CCXI Put And Call Options For August 16th
2013-12-03,ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data In ANCA-Associated Renal Vasculitis
2013-11-25,5 Stocks Poised for Breakouts
2013-11-15,4 Stocks Under $10 to Trade for Breakouts
2013-11-12,Oversold Conditions For ChemoCentryx (CCXI)
2013-11-07,ChemoCentryx Announces Financial Results For The Quarter Ended September 30, 2013
2013-11-07,Top Insider Trades: PBYI USAK RT CCXI
2013-11-06,ChemoCentryx To Present At The 2013 Credit Suisse Annual Health Care Conference
2013-11-04,Top Insider Trades: ACHN, CCXI, ACCL, WLT
2013-10-31,ChemoCentryx, Inc. To Hold Third Quarter 2013 Financial Results Conference Call On Thursday, November 7, 2013
2013-10-18,ChemoCentryx Becomes Oversold (CCXI)
2013-10-16,5 Stocks With Big Insider Buying
2013-10-11,Short Interest In ChemoCentryx Moves 91.5% Higher
2013-10-11,Top Insider Trades: CCXI HA USCR ACW
2013-10-09,5 Stocks Insiders Are Scooping Up
2013-10-08,Top Insider Trades: CCXI AYR FATE CFIS
2013-09-23,ChemoCentryx To Present At BioCentury's NewsMakers In The Biotech Industry Conference
2013-09-18,ChemoCentryx To Regain Global Rights For Vercirnon From GlaxoSmithKline
2013-09-18,4 Biotech Stocks Under $10 to Watch
2013-09-17,Ratings Changes Today
2013-09-16,Top Insider Trades: CCXI, GBDC, MVC, FUND
2013-09-10,ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
2013-09-10,ChemoCentryx Announces Top-Line Interim Results For CCX140, An Orally Administered CCR2 Inhibitor, In An Ongoing 52 Week Phase II Trial In Patients With Diabetic Nephropathy
2013-09-04,ChemoCentryx To Present At Two Upcoming Investor Conferences
2013-08-23,ChemoCentryx Announces GlaxoSmithKline's Release Of Top-Line Results From The SHIELD-1 Phase III Study Of Vercirnon
2013-08-12,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2013
2013-08-09,ChemoCentryx Is Now Oversold (CCXI)
2013-08-01,ChemoCentryx, Inc. To Hold Second Quarter 2013 Financial Results Conference Call On Monday, August 12, 2013
2013-07-25,ChemoCentryx Stock Sees Short Interest Make 124.7% Move
2013-06-26,Commit To Buy ChemoCentryx At $12.50, Earn 24.8% Annualized
2013-06-19,ChemoCentryx Announces Completion Of Target Enrollment Of CCX140 Phase II Clinical Trial In Diabetic Nephropathy
2013-06-07,Biotech Stock Mailbag: 2013 Clinical Trials Calendar
2013-06-05,ChemoCentryx To Present At Two Upcoming Healthcare Conferences And Ring Opening Bell At The NASDAQ Stock Market
2013-05-28,ChemoCentryx Announces Appointment Of Health Care Insurance Executive Ira Klein, MD, To Company's Board Of Directors
2013-05-21,ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
2013-05-15,ChemoCentryx To Host Analyst Day
2013-05-13,ChemoCentryx Announces Financial Results For The Quarter Ended March 31, 2013
2013-05-10,Short Interest In ChemoCentryx Plummets 66%
2013-05-02,ChemoCentryx, Inc. To Hold First Quarter 2013 Financial Results Conference Call On Monday, May 13, 2013
2013-05-02,ChemoCentryx To Present At Bank Of America Merrill Lynch Healthcare Conference
2013-04-22,ChemoCentryx Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Over-Allotment Option
2013-04-16,ChemoCentryx Announces Pricing Of Follow-On Offering
2013-04-15,ChemoCentryx Announces Proposed Public Offering Of Common Stock
2013-03-13,ChemoCentryx Announces 2012 Fourth Quarter And Year-End Financial Results
2013-02-28,ChemoCentryx, Inc. To Hold Fourth Quarter And Year-End 2012 Financial Results Conference Call On Wednesday, March 13, 2013
2013-02-20,ChemoCentryx To Present At Upcoming Investor Conferences
2013-02-06,ChemoCentryx To Present At 15th Annual BIO CEO & Investor Conference
2013-01-07,ChemoCentryx Advances A New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
2013-01-03,ChemoCentryx To Present At The 31st Annual J.P. Morgan Healthcare Conference
2012-10-24,ChemoCentryx To Report Data For CCX140, An Orally Administered CCR2 Inhibitor, At The American Society Of Nephrology's Kidney Week 2012
2012-10-02,ChemoCentryx Reports Data For CCX872, The Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, In A Preclinical Model Of Diabetic Nephropathy
2012-08-30,ChemoCentryx To Present At The BioCentury NewsMakers In The Biotech Industry Conference
2012-08-10,ChemoCentryx Announces Financial Results For The Quarter Ended June 30, 2012
2012-04-12,ChemoCentryx To Present At The 19th Annual Future Leaders In The Biotech Industry Conference
,
